Jan Markus Grimm active positions
| Companies | Position | Start | End |
|---|---|---|---|
AL-S Pharma AG
 AL-S Pharma AG Pharmaceuticals: MajorHealth Technology AL-S Pharma AG engages in the development and marketing of pharmaceutical products. The company was founded by Michael Salzmann on September 19, 2016 and is headquartered in Schlieren, Switzerland. | Director/Board Member | - | - |
NovaGo Therapeutics AG
 NovaGo Therapeutics AG Pharmaceuticals: MajorHealth Technology NovaGo Therapeutics AG is a biotechnology start-up company, which engages in the development and manufacture of human antibody products. It focuses on cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. Its offering includes recombinant human monoclonal antibodies targeting the nerve outgrowth inhibitor Nogo-A. The company was founded by Martin E. Schwab and Roger M. Nitsch and is headquartered in Schlieren, Switzerland. | Director/Board Member | - | - |
Neurimmune Holding AG
 Neurimmune Holding AG Pharmaceuticals: MajorHealth Technology Neurimmune Holding AG is a Swiss pharmaceutical company that was founded in 2006. The private company is based in Schlieren, Switzerland and has subsidiaries in Switzerland. Neurimmune Holding manufactures pharmaceutical products. | Director/Board Member | 2020-02-02 | - |
Career history of Jan Markus Grimm
Statistics
International
| Switzerland | 4 |
Operational
| Director/Board Member | 3 |
Sectoral
| Health Technology | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 3 |
|---|---|
AL-S Pharma AG
AL-S Pharma AG Pharmaceuticals: MajorHealth Technology AL-S Pharma AG engages in the development and marketing of pharmaceutical products. The company was founded by Michael Salzmann on September 19, 2016 and is headquartered in Schlieren, Switzerland. | Health Technology |
NovaGo Therapeutics AG
NovaGo Therapeutics AG Pharmaceuticals: MajorHealth Technology NovaGo Therapeutics AG is a biotechnology start-up company, which engages in the development and manufacture of human antibody products. It focuses on cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. Its offering includes recombinant human monoclonal antibodies targeting the nerve outgrowth inhibitor Nogo-A. The company was founded by Martin E. Schwab and Roger M. Nitsch and is headquartered in Schlieren, Switzerland. | Health Technology |
Neurimmune Holding AG
Neurimmune Holding AG Pharmaceuticals: MajorHealth Technology Neurimmune Holding AG is a Swiss pharmaceutical company that was founded in 2006. The private company is based in Schlieren, Switzerland and has subsidiaries in Switzerland. Neurimmune Holding manufactures pharmaceutical products. | Health Technology |
- Stock Market
- Insiders
- Jan Markus Grimm
- Experience
